CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Show more

1111 Main Street, Vancouver, WA, 98660, United States

https://www.cytodyn.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

330.3M

52 Wk Range

$0.19 - $0.49

Previous Close

$0.26

Open

$0.26

Volume

1,860,976

Day Range

$0.24 - $0.26

Enterprise Value

432.4M

Cash

4.982M

Avg Qtr Burn

-4.35M

Insider Ownership

0.01%

Institutional Own.

0.03%

Qtr Updated

11/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Leronlimab Details Non-alcoholic steatohepatitis	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leronlimab in comb w/trifluridine+ tipiracil (TAS-102)+ bevacizumab Details Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leronlimab Details Human immunodeficiency virus	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leronlimab Details Solid tumor/s, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leronlimab Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Leronlimab Details Graft-versus-host disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.